4.1 Article

Cervical Dilation in Second-Trimester Abortion

Journal

CLINICAL OBSTETRICS AND GYNECOLOGY
Volume 52, Issue 2, Pages 171-178

Publisher

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/GRF.0b013e3181a2b3cd

Keywords

dilation; evacuation; osmotic dilator; pharmacologic agents

Ask authors/readers for more resources

Dilation and evacuation, the most common method performed for second-trimester abortion in the United States, requires Sufficient cervical dilation to reduce the risk of complications such as cervical laceration or uterine perforation. The cervix may be prepared with osmotic dilators such as laminaria, Lamicel, or Dilapan-S, or with pharmacologic agents such as misoprostol. Dilapan-S and Lamicel achieve their maximum dilation faster than laminaria, making same-day procedures possible. Misoprostol has limited data supporting its use in this setting. Decisions regarding which method is best are clinician-dependent, and factors Such as gestational age and time allowed for preparation should be considered.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.1
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Obstetrics & Gynecology

Six-month and 1-year continuation rates following postpartum insertion of implants and intrauterine devices

Irene Woo, Sara Seifert, Dacia Hendricks, Roxanne M. Jamshidi, Anne E. Burke, Michelle C. Fox

CONTRACEPTION (2015)

Article Obstetrics & Gynecology

Safety and efficacy of the NuvaRing® Applicator in healthy females: a multicenter, open-label, randomized, 2-period crossover study

Robert Feldman, Tara L. Frenkl, Carol Yacik, Yinna Wang, Michelle C. Fox

CONTRACEPTION (2016)

Article Obstetrics & Gynecology

Postexposure prophylaxis for victims of sexual assault: treatments and attitudes of emergency department physicians

Arvind Bakhru, Julie B. Mallinger, Michelle C. Fox

CONTRACEPTION (2010)

Article Obstetrics & Gynecology

Cervical preparation for second-trimester surgical abortion prior to 20 weeks' gestation

Michelle C. Fox, Colleen M. Krajewski

CONTRACEPTION (2014)

Article Acoustics

Endometrial thickness following medical abortion is not predictive of subsequent surgical intervention

M. F. Reeves, M. C. Fox, P. A. Lohr, M. D. Creinin

ULTRASOUND IN OBSTETRICS & GYNECOLOGY (2009)

Article Obstetrics & Gynecology

Neurovascular anatomy of the adult female medial arm in relationship to potential sites for insertion of the etonogestrel contraceptive implant

Joe Iwanaga, Michelle C. Fox, Hans Rekers, Lisa Schwartz, R. Shane Tubbs

CONTRACEPTION (2019)

Article Obstetrics & Gynecology

Real world data on Nexplanon® procedure-related events: final results from the Nexplanon Observational Risk Assessment study (NORA)

Suzanne Reed, Thai Do Minh, Jens A. Lange, Carol Koro, Michelle Fox, Klaas Heinemann

CONTRACEPTION (2019)

Article Obstetrics & Gynecology

Can initial vaginal bleeding patterns in etonogestrel implant users predict subsequent bleeding in the first 2 years of use?

Diana Mansour, Ian S. Fraser, Alison Edelman, Carolina S. Vieira, Andrew M. Kaunitz, Tjeerd Korver, Annpey Pong, Jianxin Lin, Arvind K. Shah, Michelle Fox, Hans Rekers, Mitchell D. Creinin

CONTRACEPTION (2019)

Article Endocrinology & Metabolism

Corifollitropin Alfa Combined With Human Chorionic Gonadotropin in Adolescent Boys With Hypogonadotropic Hypogonadism

R. Ravi Shankar, Suneri Shah, Hee-Koung Joeng, Geraldine Mendizabal, Julia R. DiBello, Yanfen Guan, Barbara J. Stegmann, Eberhard Nieschlag, Hermann M. Behre, Ronald S. Swerdloff, Michelle C. Fox, Keith D. Kaufman

Summary: This study aimed to investigate the efficacy and safety of corifollitropin alfa (CFA) combined with hCG for inducing testicular growth and pubertal development in adolescent boys with hypogonadotropic hypogonadism (HH). The results showed that the combined treatment with CFA and hCG induced testicular growth accompanied by pubertal progression, increased testosterone levels, and a pubertal growth spurt. The treatment was generally well tolerated, with no development of antibodies against CFA.

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM (2022)

Article Obstetrics & Gynecology

Bleeding patterns after vaginal misoprostol for treatment of early pregnancy failure

AR Davis, CM Robilotto, CL Westhoff, S Forman, J Zhang

HUMAN REPRODUCTION (2004)

Article Obstetrics & Gynecology

Endometrial thickness after misoprostol use for early pregnancy failure

MD Creinin, B Harwood, RS Guido, MC Fox, J Zhang

INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS (2004)

Article Obstetrics & Gynecology

A randomized comparison of misoprostol 6 to 8 hours versus 24 hours after mifepristone for abortion

MD Creinin, MC Fox, S Teal, A Chen, EA Schaff, LA Meyn

OBSTETRICS AND GYNECOLOGY (2004)

No Data Available